DUBLIN, Dec. 13, 2023 /PRNewswire/ — The “Hypertrophic Cardiomyopathy – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hypertrophic Cardiomyopathy pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Hypertrophic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertrophic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hypertrophic Cardiomyopathy: Emerging Drugs Chapters
This segment of the Hypertrophic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypertrophic Cardiomyopathy: Emerging Drugs
Aficamten: Cytokinetics
Aficamten is an investigational, oral, small molecule cardiac myosin inhibitor. It is designed to reduce the hypercontractility associated with HCM by blocking myosin from pulling, resulting in less contraction, or fewer hands on the rope. The drug is in the study, SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase III randomized, placebo-controlled, double blind, multi-center clinical trial designed to evaluate aficamten in patients with symptomatic obstructive HCM on background medical therapy for 24 weeks.
Ninerafaxstat: Imbria
Ninerafaxstat is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, ninerafaxstat is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency.
The drug is currently being investigated in three Phase II proof-of-concept clinical trials in patients with non-obstructive HCM. IMPROVE-HCM Phase II clinical trial is a randomized, double-blind, placebo-controlled clinical trial investigating the safety and efficacy of ninerafaxstat in patients with non-obstructive HCM.
TN-201: Tenaya Therapeutics
TN-201, an adeno-associated virus (AAV)-based gene therapy designed to treat adults and children with HCM due to MYBPC3 gene mutations, the most prevalent form of genetic HCM. TN-201 is intended to address the underlying cause of disease by delivering a fully functional MYBPC3 gene to restore normal levels of MYBPC3 protein with the hope of potentially halting disease progression and reversing the course of genetic HCM after a single treatment.
Recently in 2023, the company has received clearance of the Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to begin clinical testing of TN-201. The company initiated Phase Ib clinical trial enrolling symptomatic adults who have been diagnosed with MYBPC3-associated non-obstructive HCM and expect to begin patient dosing in the third quarter of 2023.
Hypertrophic Cardiomyopathy: Therapeutic Assessment
This segment of the report provides insights about the different Hypertrophic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Hypertrophic Cardiomyopathy
There are approx. 10+ key companies which are developing the therapies for Hypertrophic Cardiomyopathy. The companies which have their Hypertrophic Cardiomyopathy drug candidates in the most advanced stage, i.e. phase III include, Cytokinetics.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hypertrophic Cardiomyopathy drugs?
- How many Hypertrophic Cardiomyopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertrophic Cardiomyopathy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypertrophic Cardiomyopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hypertrophic Cardiomyopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Cytokinetics
- Imbria
- Bristol-Myers Squibb
- Tenaya Therapeutics
- Lexeo Therapeutics, Inc.
- BioMarin
Key Products
- Aficamten
- Ninerafaxstat
- MYK-224
- TN-201
- LX2022
- BMN 293
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Hypertrophic Cardiomyopathy: Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/2540se
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo – https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:SOURCE Research and Markets
